BioNTech, OncoC4: Positive Phase 1/2 Data for Antibody n Hard-to-Treat NSCLC at ASCO

 

• BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications, including non-small cell lung cancer (NSCLC)
• Interim data of BNT316/ONC-392 from the ongoing Phase 1/2 trial to be presented at this year’s ASCO Annual Meeting demonstrate encouraging signs of clinical anti-tumor activity and a manageable safety profile in patients with metastatic, PD-(L)1-resistant NSCLC
• Initiation of a pivotal Phase 3 trial with BNT316/ONC-392 as monotherapy in immunotherapy-resistant NSCLC patients is planned in Q3 2023, following FDA’s Fast Track designation in 2022
• Lung cancer remains one of the most commonly diagnosed malignant cancer types and the leading cause of cancer deaths worldwide, with NSCLC¹ making up approximately 85% of all lung cancers

https://www.biospace.com/article/releases/biontech-and-oncoc4-present-positive-phase-1-2-data-for-antibody-candidate-bnt316-onc-392-in-hard-to-treat-nsclc-at-asco-/